-

Pfizer Declares Fourth-Quarter 2025 Dividend

Board of Directors approves quarterly cash dividend of $0.43 per share

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company’s common stock, payable December 1, 2025, to holders of the Common Stock of record at the close of business on November 7, 2025. The fourth-quarter 2025 cash dividend will be the 348th consecutive quarterly dividend paid by Pfizer.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Category: Financial

Contacts

Media Contact: PfizerMediaRelations@Pfizer.com

Investor Contact: IR@Pfizer.com

Pfizer Inc.

NYSE:PFE

Release Versions

Contacts

Media Contact: PfizerMediaRelations@Pfizer.com

Investor Contact: IR@Pfizer.com

More News From Pfizer Inc.

Pfizer Responds to Delaware Chancery Court Ruling

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc. from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk. “We remain confident in the merits of our claims and our belief that Metsera has acted in breach of its contractual obligations and that Metsera’s directors have breached the...

Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware. The lawsuit asserts that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action by Novo Nordisk to protect its dominant market position in GLP-1s by capturing and killing a nascent American competitor before it gains the support of Pfiz...
Back to Newsroom